TXG vs. OLK, CTKB, BIO.B, BIO, ARWR, FOLD, AZTA, PGNY, JANX, and IMCR
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Olink Holding AB (publ) (OLK), Cytek Biosciences (CTKB), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), Azenta (AZTA), Progyny (PGNY), Janux Therapeutics (JANX), and Immunocore (IMCR). These companies are all part of the "medical" sector.
10x Genomics (NASDAQ:TXG) and Olink Holding AB (publ) (NASDAQ:OLK) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
In the previous week, Olink Holding AB (publ) had 7 more articles in the media than 10x Genomics. MarketBeat recorded 12 mentions for Olink Holding AB (publ) and 5 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.90 beat Olink Holding AB (publ)'s score of -0.09 indicating that 10x Genomics is being referred to more favorably in the media.
Olink Holding AB (publ) has lower revenue, but higher earnings than 10x Genomics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Olink Holding AB (publ) has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
Olink Holding AB (publ) has a net margin of -19.72% compared to 10x Genomics' net margin of -42.20%. Olink Holding AB (publ)'s return on equity of -7.00% beat 10x Genomics' return on equity.
10x Genomics presently has a consensus target price of $48.50, suggesting a potential upside of 83.78%. Olink Holding AB (publ) has a consensus target price of $26.00, suggesting a potential upside of 8.29%. Given 10x Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe 10x Genomics is more favorable than Olink Holding AB (publ).
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 30.2% of Olink Holding AB (publ) shares are held by institutional investors. 10.7% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
10x Genomics received 29 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.
Summary
10x Genomics beats Olink Holding AB (publ) on 11 of the 18 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10x Genomics Competitors List
Related Companies and Tools
